Pilot RCT in 41 people with HIV who smoke: an HIV-tailored digital therapeutic vs QuitGuide increased engagement; verified 7-day abstinence at 12 weeks (secondary) was not significantly different (18.2% vs 15.8%).
RCTn = 41
Vilardaga et al. Population reach, feasibility and acceptability of digital therapeutics for smoking cessation among people living with HIV: Results of the Quitting Matters pilot trial